Prospects for the management of diabetic neuropathy
https://doi.org/10.14341/2072-0351-5638
Abstract
Diabetic peripheral neuropathy (DPN) is one of the most common chronic complications of diabetes mellitus leading to deterioration of the patientsquality of life. Effective methods for the treatment of DPN and improvement of both quality of life and long-term prognosis of the disease remain tobe developed.To review pathogenetic mechanisms of DPN, the known methods of DPN treatment and the influence of activation of PPAR-alpha receptors onpathogenesis and outcome of DPN.
About the Authors
Alexandr Sergeevich Ametov
Russian Medical Academy of Postdiploma Education, Moscow
Marina Alexandrovna Lysenko
Russian Medical Academy of Postdiploma Education, Moscow
References
1. Young M.J., Boulton A.J.M., Macleod A.F., Williams D.R.R., Sonksen P.H. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population // Diabetologia. - 1993. - № 36. - Р. 150-154.
2. Ziegler D., Gries F.A. Nervenheilkunde. - 1993. - № 12. - Р. 405-410.
3. Аметов А.С. Сахарный диабет. Проблемы и решения. М.: ГЭОТАР- Медиа, 2011. - 680 с.
4. King R.H. The role of glycation in the pathogenesis of diabetic polyneuropathy // Mol. Pathol. - 2001. - № 54. - Р. 400-408.
5. Ziegler D., Sohr C.G.H., Nourooz-Zadeh J. Oxidative Stress and Antioxidant Defense in Relation to the Severity of Diabetic Polyneuropathy and Cardiovascular Autonomic Neuropathy // Diabetes Care. - 2004. - № 27. - Р. 2178-2183.
6. Доказательная эндокринология / Перевод с англ. - 2-е изд. - М.: ГЭОТАР-Медиа, 2008. - 640 с.
7. Ametov A., Barinov A., O'brien P., Dyck P.J., Herman R., lLitchy W.J. et al, the SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: The SYDNEY Trial // Diabetes Care. - 2003. - № 26. - Р. 770-776.
8. Ziegler D., Nowak H., Kempler P., Vargha P., Low P.A. Treatment of symptomatic diabetic polyneuropathy with the anti-oxidant alphalipoic acid: a meta-analysis // Diabetic Medicine. - 2004. - № 21. - Р. 114-121.
9. Ziegler D., Ametov A., Barinov A. et al. Oral Treatment With Alpha- Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy - The SYDNEY 2 Trial // Diabetes Care. - 2006. - № 29. - Р. 2365-2370.
10. Ziegler D., Low P.A., Boulton A.J.M. et al. Effect of a 4-year Antioxidant Treatment with alpha-Lipoic Acid in Diabetic Polyneuropathy: The NATHAN 1 Trial. Abstract Number: 0007-OR, vorgestellt beim 67th ADA Kongress in Chicago, 22. bis 26. Juni 2007.
11. Ziegler D., Movsesyan L., Mankovsky B., Gurieva I., Abylaiuly Z., Strokov I. Treatment of Symptomatic Plyneuropathy With Actovegin in Type 2 Diabetic patients // Diabetes Care. - 2009. - № 8. - Р. 1479-1484.
12. Feingold K.R. The importance of lipids in cutaneous function // J. Lipid. Res. - 2007. - № 48. - Р. 2529-3030.
13. Losada M., Alio J.L. Malondialdehyde serum concentrationin type 1 diabetic with and without retinopathy // Doc Ophthalmol. - 1997. - № 93. - Р. 223-229.
14. Tordjman, K., et al. PPAR deficiency reduces insulin resistance and atherosclerosis in ApoE-null mice // J. Clin. Invest. - 2001. - № 107. - Р. 1025-1034.
15. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., Drury P., Kesäniemi Y.A., Sullivan D., Hunt D., Colman P., d'Emden M., Whiting M., Ehnholm C, Laakso M; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial // Lancet. - 2005. - № 366 (9500). - Р. 1849-1861.
16. ACCORD Study Group // N Engl J Med. - 2010. - March 14. Epub.
17. Rajamani K., Donoghoe M., et al. 78th EAS Congress // Atherosclerosis Supplements. - 2010. - № 112. - Р. 219-220.
18. Ganesaratnam K. // Biochemical and Pharmocology. - 2005. - № 70. - P. 1653-1663.
19. Lefebvre P., Chinetti G., Fruchart J. Staels B. Sorting out the roles of PPAR-a in energy metabolism end vascular homeostasis // J. Clin. Invest. - 2006. - Mar;116(3). - P. 571-580.
Review
For citations:
Ametov A.S., Lysenko M.A. Prospects for the management of diabetic neuropathy. Diabetes mellitus. 2011;14(2):70-73. (In Russ.) https://doi.org/10.14341/2072-0351-5638
Views:
1116
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
